

ABSTRACT TOPIC LIST (revised Dec 2018)

A: Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development

A1 Preclinical and translational aspects

A11 Preclinical aspects

- A111 Animal models and in-vitro studies
- A112 Tumor biology
- A113 Biology, benign disease

A12 Translational aspects

- A121 Cardiology
- A122 Neurology
- A123 Oncology (Translational)
- A124 Therapy

A2 Radiopharmacy, radiochemistry, drug development

A21 Drug development

- A211 Radiopharmacokinetics and drug development
- A212 New biological targets and ligands

A22 Radiopharmacy

- A221 Radiopharmaceuticals - SPECT
- A222 Radiopharmaceuticals - PET
- A223 Radiopharmaceuticals – Therapy
- A224 Radiopharmaceuticals – Multimodal / optical probes
- A225 Quality Control & Quality Assurance

A23 Radiochemistry

- A231 Radionuclide Production
- A232 Radiopharmaceutical Preparation

B: Technical aspects

B3 Instrumentation and data analysis

B31 Instrumentation

- B311 General aspects
- B312 Metric and intervention
- B313 SPECT and SPECT/CT
- B314 PET and PET/CT
- B315 PET/MR
- B316 Optical imaging
- B317 Imaging guided surgery

B32 Data analysis

- B321 Data analysis and management
- B322 Image reconstruction
- B323 Artificial intelligence and Radiomics
- B324 Quality control, performance and standardization
- B325 Neurology: data analysis and quantification
- B326 Cardiology: data analysis and imaging systems

B4 Radiation protection and dosimetry

B41 Radiation protection

- B411 Radiation Exposure & Protection

B42 Dosimetry and radiobiology

- B421 Preclinical studies
 - B4211 Preclinical dosimetry
 - B4212 Preclinical radiobiology
- B422 Clinical studies
 - B4221 Clinical dosimetry
 - B4222 Clinical radiobiology

C: Clinical

C5 Diagnostic study

C51 Adult study

C511 Oncology study

C511-1 General oncology

- C511-1a Radioguided surgery
- C511-1b External beam radiation therapy planning
- C511-1c Therapy response assessment

C511-2 Organ-based oncology

- C511-2a Brain, malignant
- C511-2b Head and neck, malignant
- C511-2c Breast, malignant
- C511-2d Lung, malignant
- C511-2e Liver, Upper GI and Pancreatic (non-endocrine), malignant

C511-2f Colorectal, malignant

C511-2g Prostate, malignant

C511-2h Other urological, malignant

C511-2i Gynaecological, malignant

C511-2j Hemato-oncology, malignant

C511-2k Bone and soft tissues primary and metastatic cancers

C511-2l Melanoma, malignant

C511-2m Endocrine, malignant

C511-2n Thyroid, malignant

C511-2o Other malignant, including primary of unknown origin

C512 Non-oncology study

C512-1 Cardiovascular

C512-1a Perfusion, metabolism and receptors

C512-1b Plaque and vascular imaging

C512-1c Lymphatic imaging (non-oncology)

C512-2 Neurology

C512-2a Neurodegeneration and dementia

C512-2b Psychiatry

C512-2c Neurotransmission

C512-2d Movement disorders

C512-2e Other Neurology (i.e.: neuroinflammation, epilepsy, headache)

C512-3 Endocrinology

C512-3a Endocrinology, benign

C512-3b Thyroid, benign

C512-4 Musculoskeletal, infection and inflammation

C512-4a Orthopedics, benign, no infection

C512-4b Bone inflammation and infection

C512-4c Soft tissue inflammation and infection (including cardiac, lung, brain, etc.)

C512-5 Other clinical studies

C512-5a Pulmonology, benign

C512-5b Gastroenterology, benign

C512-5c Uro-nephrology, benign

C512-5d Hematology, benign

C52 Paediatric study

C521 Oncology (Diagnostic)

C522 Benign (Diagnostic)

C6 Therapy study

C61 Adult study

C611 Thyroid treatment

C6111 Thyroid treatments, benign

C6112 Thyroid treatments, malignant

C612 Other treatments

C6121 NET treatments, including mIBG and peptides therapy

C6122 Radioimmunotherapy

C6123 Bone metastases, pain palliation

C6124 Prostate cancer specific treatments

C6125 Local radionuclide treatments

C6126 Other treatments

C62 Paediatrics study

C621 Oncology (Therapy)

C622 Benign (Therapy)